Breaking Finance News

Zacks Investment Research upgraded Merrimack Pharmaceuticals Inc (NASDAQ:MACK) to Hold in a report released today.

Zacks Investment Research has upgraded Merrimack Pharmaceuticals Inc (NASDAQ:MACK) to Hold in a report released on Wednesday October 05, 2016.

Just yesterday Merrimack Pharmaceuticals Inc (NASDAQ:MACK) traded -8.36% lower at $5.93. Merrimack Pharmaceuticals Inc’s 50-day moving average is $5.20 and its 200-day moving average is $6.20. The last stock price is down -11.57% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 5,148,851 shares of MACK traded hands, up from an average trading volume of 2,614,400

Recent Performance Chart

Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Merrimack Pharmaceuticals Inc has 52 week low of $4.39 and a 52 week high of $10.85 and has a market capitalization of $0.

Brief Synopsis On Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.